Puma Biotechnology (PBYI) Insider Edward Sells $78K of Stock

Wilson Troy Edward sold 10,800 shares of Puma Biotechnology, Inc. (PBYI) on June 12, 2026. The transaction was valued at roughly $77,760 and was disclosed in a recent filing with the Securities and Exchange Commission. This sale was not an isolated event, as several other leaders at the company also trimmed their holdings on the same date.

Coordinated Insider Activity

The sale by Wilson Troy Edward was executed at an average price of $7.20. It followed a pre-arranged Rule 10b5-1 trading plan, which is a schedule insiders use to trade their own company's stock at set times to avoid any appearance of using private information. Several peers also sold shares on June 12, 2026. Adrian Senderowicz sold 27,000 shares for $194,400, while Jay Moyes sold 22,000 shares at a slightly higher average price of $7.22. Brian Stuglik also participated, selling 8,100 shares at the $7.20 mark.

Puma Biotechnology Stock Trends

On Tuesday, the stock was trading around $7.07. This price level is quite close to the company's 200-day moving average of $7.28, a technical line that many traders watch to gauge long-term momentum. Over the last 52 weeks, the stock has fluctuated between a low of $4.47 and a high of $9.75. With a price-to-earnings (P/E) ratio of 18.8, the company is currently profitable, though its forward P/E of 27.4 suggests investors are paying a premium for expected future earnings.

Recent Earnings and Growth

In its most recent financial reporting period, Puma Biotechnology brought in $231.24 million in revenue, which reflects a growth rate of 7.8%. The company is maintaining a healthy net margin of 11.55% and a return on equity of 21.97%. These figures show the firm is effectively turning its sales into profit. Investors are waiting for the next update on these fundamentals when the company reports earnings again on November 5, 2026.

Analysts Set New Price Targets

Market experts have been cautious about the stock's ceiling. On August 7, 2026, analysts at TD Cowen kept a Hold rating on the shares. While they did not see a reason to buy aggressively, they did lift their price target from $5.00 to $6.00. This suggests that while the company is meeting expectations, analysts aren't yet convinced there is significant room for the stock to run much higher than its current levels.

About Puma Biotechnology

Puma Biotechnology is a biopharmaceutical firm focused on improving cancer care. Its primary product is Nerlynx, a drug used to help treat specific types of aggressive breast cancer. The company also works on developing other small-molecule inhibitors to fight lung and head and neck cancers. Based in Los Angeles, Puma relies on partnerships with major players like Pfizer to help manufacture and distribute its treatments globally.

What's Ahead for Puma Biotechnology, Inc.

As the company approaches its November earnings date, investors will likely watch for updates on Nerlynx sales and progress in its clinical pipeline. While the recent cluster of insider sales might catch the eye of some observers, these planned transactions often happen regardless of a company's day-to-day performance. Further filings in the coming months will reveal if the executive team continues to pare back their positions or if the current selling phase has concluded.